Lula's Win Rattles Wall Street's Brazil Trio
Published on 28 October 2026
Read article
Listen to article
6:51Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Let’s be honest, the “future” has been a bit of a letdown. For decades, we were promised jetpacks, meals in pill form, and colonies on Mars. Instead, we got social media and slightly faster broadband. But I think we’re finally at a turning point. Beneath the noise and the endless hype, a few genuinely world changing ideas are not just taking shape, they are creating markets that could redefine how we think about growth. These are not speculative fantasies, but tangible shifts in technology that investors ought to be watching very closely.
Every time someone mentions flying cars, I feel a familiar wave of cynicism. It’s the ultimate sci-fi cliché. Yet, here we are. A company like EHang Holdings is not just building prototypes in a shed, it is actually getting regulatory approval in China for autonomous flying vehicles. Think of them less as cars and more as automated air taxis, designed to hop over the gridlocked traffic that plagues every major city on earth.
To me, the real story isn’t the novelty of flying. It’s the solution to a cripplingly expensive problem, urban congestion. The opportunity is enormous, but let’s not get carried away. The path is littered with regulatory hurdles and the small matter of convincing the public to trust a pilotless pod in the sky. It’s a long game, but one with a potential prize that is almost too big to calculate.
While flying machines grab the headlines, a quieter, perhaps more profound revolution is happening in our pharmacies. For years, tackling obesity has been a frustrating cycle of diet fads and public health lectures. Now, companies like Novo Nordisk have developed drugs that do more than just suppress appetite, they seem to fundamentally rewire the body’s metabolic system.
The results have been nothing short of staggering, achieving weight loss previously only possible through surgery. The market is, frankly, colossal. With hundreds of millions of people affected by obesity globally, the financial implications are mind boggling. Novo Nordisk has a significant head start, but the race is on. This isn’t just about vanity, it’s about potentially reducing rates of heart disease and diabetes on a global scale. It’s a healthcare breakthrough that also happens to be a multi-billion dollar commercial opportunity.
While we’ve all been distracted, robots have been steadily making their way into our hospitals. Intuitive Surgical and its da Vinci system have, without much fanfare, completely changed complex surgery. Surgeons now use robotic arms to perform procedures with a level of precision the human hand simply cannot match. This means smaller incisions, less trauma for the patient, and faster recovery times.
From an investor’s point of view, the business model is beautiful in its simplicity. The company doesn’t just sell a hospital a very expensive robot. It then sells the disposable instruments and accessories for every single procedure. It’s the classic razor and blade model, creating a stream of recurring revenue that is the envy of the medical world. This isn't a bet on a future trend, it's an investment in a revolution that is already well underway. Trying to pick individual winners in these fields can feel like a fool's errand, however. A more pragmatic approach, I think, is to look at the broader themes. A collection like the Future Tech: World Changing Ideas basket, for instance, bundles these ideas together, which may help spread the risk.
View the full Basket:Future Tech: World Changing Ideas
View the full Basket:Future Tech: World Changing Ideas
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 28 October 2026
Read article
Published on 27 October 2026
Read article
Published on 26 October 2026
Read article
Published on 24 October 2026
Read article
Published on 24 October 2026
Read article